Recanalisation therapies for acute ischaemic stroke in patients on direct oral anticoagulants

David J Seiffge, Thomas Meinel, Jan Christoph Purrucker, Johannes Kaesmacher, Urs Fischer, Duncan Wilson, Teddy Y Wu

ABSTRACT
Direct oral anticoagulants (DOACs) have emerged as primary therapeutic option for stroke prevention in patients with atrial fibrillation. However, patients may have ischaemic stroke despite DOAC therapy and there is uncertainty whether those patients can safely receive intravenous thrombolysis or mechanical thrombectomy. In this review, we summarise and discuss current knowledge about different approaches to select patient. Time since last DOAC intake—as a surrogate for anticoagulant activity—is easy to use but limited by interindividual variability of drug pharmacokinetics and long cut-offs (>48 hours). Measuring anticoagulant activity during drug-specific coagulation assays showed promising safety results. Large proportion of patients at low anticoagulant activity seem to be potentially treatable but there remains uncertainty about exact safe cut-off values and limited assay availability. The use of specific reversal agents (ie, idarucizumab or andexanet alfa) prior to thrombolysis is a new emerging option with first data reporting safety but issues including health economics need to be elucidated. Mechanical thrombectomy appears to be safe without any specific selection criteria applied. In patients on DOAC therapy with large vessel occlusion, decision for intravenous thrombolysis should not delay thrombectomy (eg, direct thrombectomy or immediate transfer to a thrombectomy-capable centre recommended). Precision medicine using a tailored approach combining clinical and radiological information (ie, penumbra and vessel status), anticoagulant activity and use of specific reversal agents only if necessary seems a reasonable choice.

INTRODUCTION
Oral anticoagulation using direct oral anticoagulants (DOACs) has emerged as the primary therapeutic option for stroke prevention in patients with non-valvular atrial fibrillation. Furthermore, DOACs are used for treatment of other vascular diseases (ie, intracardiac thrombus, stable coronary heart disease, venous thrombosis) and trials assessing further indications (ie, patent foramen ovale) are ongoing. However, patients may have ischaemic stroke despite DOAC therapy1,2 and recent reports found up to 13% of all patients who had a stroke to be on anticoagulant therapy prior to stroke onset with rapidly increasing numbers of DOAC.3 Intravenous thrombolysis (IVT) and mechanical thrombectomy are the cornerstone of acute stroke therapy to reduce morbidity and improve functional outcome.4 Acute recanalisation therapies bear the risk of haemorrhagic transformation of the infarcted brain tissue leading to symptomatic intracranial haemorrhage. The rate of symptomatic intracranial haemorrhage ranges between 3.7% (IVT only),4 5.1% (mechanical thrombectomy with thrombolysis)5 and 4.3% (mechanical thrombectomy alone).6

In contrast to therapy with vitamin K antagonists (VKAs) which result in a broad, long lasting unselected inhibition of the coagulation cascade by inhibition of the proper synthesis of several coagulation factors (factors II, VII, IX und X), DOACs directly target selected factors in the coagulation cascade, either thrombin (dabigatran) or factor Xa (apixaban, rivaroxaban and edoxaban). Onset of the anticoagulatory effect of DOACs is quick (peak levels between 2 and 5 hours after intake) and last only for several hours to a few days. Measuring DOAC activity is challenging and there are currently no point-of-care devices approved for DOAC measurement. In contrast, monitoring anticoagulant activity in patients taking VKA using point-of-care international normalised ratio (INR) testing is easy and results are rapidly available.7 Among patients with DOAC having a stroke, approximately 28% are potentially eligible for IVT (within 4.5 hours time window, National Institutes of Health Stroke Scale (NIHSS) ≥4).8

In analogy to thrombolysis in patients on VKA, current approaches to select patients on DOAC treatment for recanalisation therapies try to identify those patients at low anticoagulant activity to minimise the risk of symptomatic intracranial haemorrhage. Indeed, pioneering studies11–14 found that DOAC therapy does not seem to increase the risk of symptomatic intracranial haemorrhage following IVT in such selected patients. Despite this, there remains uncertainty among stroke physicians on how to select such patients. Indeed, in a multicentre German registry study only 6% of patients on DOACs eligible for thrombolysis received such treatment with DOAC therapy being the reason to withhold thrombolysis in most cases.9 In a Swiss study, only 15% of potentially eligible patients with atrial fibrillation on DOAC therapy received thrombolysis but there seemed to be no barrier to the use of mechanical thrombectomy.8 Reflecting the still limited evidence, the American Heart/Stroke Association guidelines do not make strong recommendations on the use of IVT in patients taking DOAC, in fact they state intravenous alteplase may even be harmful unless routine labs or Xa activity

Correspondence to
Dr David J Seiffge, Neurology and Stroke Center, Inselspital Universitätsklinik Bern, Bern, Switzerland; david.seiffge@insel.ch

Received 25 October 2020
Revised 12 December 2020
Accepted 23 December 2020
Published Online First 4 February 2021

To cite: Seiffge DJ, Meinel T, Purrucker JC, et al. J Neurol Neurosurg Psychiatry 2021;92:534–541. doi:10.1136/jnnp-2020-325456

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
are normal or the patient has not taken a dose in >48 hours. Recent approval of targeted reversal agents for dabigatran (idarucizumab) and apixaban/rivaroxaban (andexanet alfa) offers a new, unprecedented additional option.

In this review, we recapitulate the current understanding of haemorrhagic transformation in acute ischaemic stroke and the role of thrombin, the major treatment target of DOACs, in this process. We present current concepts of patient selection in those taking DOAC and summarise available data for different approaches. Finally, we summarise data on mechanical thrombectomy in patients taking DOAC and whether specific patient selection is warranted.

**PATHOPHYSIOLOGY, CLASSIFICATION AND THE ROLE OF THROMBIN IN HAEMORRHAGIC TRANSFORMATION AFTER ACUTE ISCHAEMIC STROKE**

Haemorrhagic transformation of infarcted brain tissue may occur spontaneously after acute ischaemic stroke but acute recanalisation therapies increase the risk. The spectrum of haemorrhagic transformation ranges from scattered small petechiae to large parenchymal bleeding with substantive mass effect (figure 1). Usually, haemorrhagic transformation is classified according to radioclinical criteria developed for large thrombolysis trials (European Cooperative Acute Stroke Study /National Institute of Neurological Disorders and Stroke Trial) using CT imaging and associated worsening of the neurological function (measured using the NIHSS) ranging from haemorrhagic infarction to symptomatic intracerebral haemorrhage (sICH). sICH is associated with substantial mortality and morbidity.

The pathophysiology leading to haemorrhagic transformation is complex. Disruption of the blood–brain barrier increasing vascular permeability plays a major role in haemorrhagic transformation. The effect of therapeutic anticoagulation on haemorrhagic transformation is probably mediated through the different mode of action and the pivotal role of thrombin inhibition by DOACs. Nevertheless, as direct translation of animal data to human patients is not possible, cautious approaches for clinical practice are warranted.

**DRUG MONITORING IN DOACS**

Assessing anticoagulant activity in DOACs in the emergency setting (in analogy to patients taking VKA) is fundamental but not straightforward. Difficulties include test availability and turn-around time, lack of clear cut-off values and test variability. Conventional, unspecific tests (ie, INR, activated partial thrombin time (aPTT), thrombin time (TT)) along with drug-specific tests have been used to monitor DOAC activity.

Recent systematic reviews and the latest International Committee for Standardization in Haematology and International Committee on Thrombosis and Haemostasis recommendations can be summarised as follows: (1) prothrombin time (PT)/INR and aPTT are not reliable tests to assess DOAC concentration, (2) current non-specific point of care testing lacks responsiveness to detect DOAC presence and (3) tandem mass spectrometry remains the gold standard; however, drug-calibrated dilute thrombin time, ecarin chromogenic assay, ecarin clotting time, anti-FIIa and anti-FXa are suitable for rapid quantitation of DOACs.

Although not recommended, some information can be derived from unspecific coagulation tests: a normal TT can rule out relevant concentrations of dabigatran. Anti-Xa inhibitors show some degree of correlation with aPTT and PT/INR; however, results are hampered by overall poor correlations, significant reagent dependent sensitivities and variability within assays. Studies in patients with acute stroke show similar results with normal aPTT and INR in 11%–44% of patients with peak DOAC drug levels.

Mass spectrometry measurements are considered the gold standard as drug-specific assays for DOAC measurement but it is unsuitable for emergency situation. Outside of mass spectrometry, only ecarin clotting time (for dabigatran) and calibrated anti-Xa assays (for Xa-inhibitors) show linear correlations to anticoagulant activity. Conventional, unspecific tests (ie, INR, activated partial thrombin time (aPTT), thrombin time (TT)) along with drug-specific tests have been used to monitor DOAC activity.

Figure 1 Haemorrhagic transformation on CT ranging from haemorrhagic infarction type I (HI1) to parenchymal haemorrhage type 2 (PH2). Haemorrhagic transformation can occur outside the infarcted brain tissue (‘remote haemorrhage’). Left part of each pair CT is the initial perfusion imaging showing infarct core (red) and penumbra (green), and the right part is the postreperfusion CT.
Cerebrovascular disease

Table 1 Characteristics of different direct oral anticoagulants

|                  | Dabigatran | Rivaroxaban | Apixaban | Edoxaban |
|------------------|------------|-------------|----------|----------|
| Half-life        | 13 hours   | 5–13 hours  | 12 hours | 12 hours |
| Time to peak     | 1.5–3 hours| 2–3 hours   | 3–4 hours| 1–2 hours|
| Oral bio-availability | 3%–7%     | 80%–100%    | 50%      | 60%      |
| Renal clearance  | 80%        | 70%         | 45%      | 50%      |
| Suggested reversal agents | Not useful | Calibrated anti-Xa assays | Calibrated anti-Xa assays | Calibrated anti-Xa assays |
| Reversal agents  | Idarucizumab (approved for use prior to urgent interventions) | Andexanet alfa (no approval for urgent interventions) | (Andexanet alfa not yet approved) |

modification of thromboelastography testing incorporating an anti-Xa assay and an ecarin clotting time into a cartridge) but their relevance in acute stroke care is currently not clear. Most promising, an investigator led prospective study investigating a point of care DOAC device (ClinicalTrials.gov Identifier: NCT02825394) has recently been completed and publication of the final results is eagerly awaited. Bed-side testing of relevant concentrations >30 ng/mL has shown acceptable sensitivity and specificity for rivaroxaban and edoxaban, as well as dabigatran, by using the Hemochron Signature Elite system. Finally, as prior studies found that Roche CoaguChek showed good calibration laboratories having access, respectively. However, 18 of only 1.5% and 22% of Australasia and North America coagulation laboratories have access, respectively. This was often not clearly reported. Table 3 provides an overview on different DOACs and their characteristics.

Current guideline recommendations from national and international associations differ significantly in their conclusions (see table 2). The Japanese consensus statement recommends the use of recombinant tissue Plasminogen Activator (rt-PA) with a dosage of 0.6 mg/kg according to local guidelines.

NON-SELECTIVE APPROACH TO IVT

There is a considerable number of case reports on patients receiving thrombolysis for acute ischaemic stroke despite being on DOAC therapy (over 40 case reports with >50 patients) with 3 patients having sICH after thrombolysis which has been summarised in a recent review. However, case reports are subject of selection and publication bias. Furthermore, general laboratory coagulation profile appeared to be part of eligibility assessment in several studies but the approach to selection was often not clearly reported. Table 1 provides an overview on available observational data including all studies with more than five patients on DOAC (first paragraph ‘heterogeneous or unknown selectin criteria’: 5 studies with 475 patients). In a Japanese national cohort, 76 patients on DOACs received IVT (15 also had additional mechanical thrombectomy) without any levels or the use of specific reversal agents (ie, idarucizumab for dabigatran and andexanet alfa for factor Xa inhibitors) to neutralise DOAC activity. Table 1 provides an overview on different DOACs and their characteristics.

PATIENT SELECTION AND CURRENT GUIDELINE RECOMMENDATIONS

Different approaches have been proposed including time since last DOAC intake, drug monitoring using unspecific (ie, INR) or drug-specific coagulation assays (ie, DOAC plasma levels) or the use of specific reversal agents (ie, idarucizumab for dabigatran and andexanet alfa for factor Xa inhibitors) to neutralise DOAC activity. Table 1 provides an overview on different DOACs and their characteristics.

Current guideline recommendations from national and international associations differ significantly in their conclusions (see table 2). The Japanese consensus statement recommends the use of recombinant tissue Plasminogen Activator (rt-PA) with a dosage of 0.6 mg/kg according to local guidelines.

Table 2

| American Heart/Stroke Association | The use of intravenous alteplase in patients taking direct thrombin inhibitors or direct factor Xa inhibitors has not been firmly established but may be harmful. Intravenous alteplase should not be administered to patients taking direct thrombin inhibitors or direct factor Xa inhibitors unless laboratory tests such as aPTT, INR, platelet count, ecarin clotting time, thrombin time or appropriate direct factor Xa activity assays are normal or the patient has not received a dose of these agents for >48 hours (assuming normal renal metabolising function). |
| Japanese consensus statement | For dabigatran IVT is not recommended if aPTT >1.5 times or last dose is <4 hours. In this case, IVT can be considered after intravenous administration of idarucizumab. For factor Xa inhibitors IVT is not recommended if INR exceeds at least 1.7. IVT is not recommended if the time of the last dose is <4 hours. IVT can be considered if the time of the last dose is ≥4 hours and the level of INR is ≤3.7. IVT after emergent reversal of prolonged INR using antidotes for other anticoagulants is not recommended. |
| ESO Karolinska Stroke Update 2018 | Patients with acute ischaemic stroke under VKA or DOAC treatment with proven large vessel occlusion should be offered IVT (if feasible) and endovascular treatment (thrombectomy). Thrombolysis allowed if DOAC plasma levels <30 ng/mL. If no DOAC plasma levels available, INR measurement using Hemochron Signature Elite is possible under specific circumstances. |
| French Society of Vascular Neurology | IVT if no intake >48 hours or DOAC level <50 ng/mL. Conventional testing with TT, aPTT, PT and anti-Xa levels may be used (DOAC dependant). In the case of dabigatran, reversal with idarucizumab may also be considered. |
| Australian guidelines | Comparable to French Society of Vascular Neurology |

aPTT, activated partial thrombin time; DOAC, direct oral anticoagulant; INR, international normalised ratio; IVT, intravenous thrombolysis; PT, prothrombine time; TT, thrombin time; VKA, vitamin K antagonist.
sICH within 24 hours of treatment.\(^\text{10}\) In this cohort, IVT with rt-PA was used with a dosage of 0.6 mg/kg. Similarly, in the Get With the Guidelines Stroke registry, the sICH rate was 4.8% (12 patients from 251 patients on DOACs who received IVT). However, time since last DOAC intake was up to 7 days in this study.\(^\text{12}\) An international collaboration of European and Japanese stroke centres published data of 78 DOAC patients (rivaroxaban = 47) treated with IVT. Although nearly half (23/47) of the rivaroxaban patients recommended for IVT on the basis of low plasma rivaroxaban level (<100 ng/mL),\(^\text{11}\) many patients were selected using different approaches and no conclusion about one single selection criterion can be drawn from this study. The overall reported rate of sICH in this study was 2% (2 patients) and none of the patients selected using DOAC plasma levels had sICH. Data from the Swiss Stroke Registry of 69 patients on DOACs receiving IVT found no increased risk of sICH compared with patients without anticoagulation and those on VKAs with INR ≤ 1.7.\(^\text{13}\) (18 of 23 centres used DOAC plasma levels for patient selection).

### Selection by Time Since Last Intake

The predictable pharmacokinetics and dynamics of DOACs (table 1) has made time since last intake the basis of most guidance for patient selection although based on limited evidence.\(^\text{11-14}\)\(^\text{46}\) Time since last dose of greater than 48 hours has generally been considered a safe time frame for intervention as this represents approximately four half-lives. However, evidence suggests time since last intake can be a poor correlate for drug activity measured on admission in patients who had a stroke using a drug-specific coagulation assay.\(^\text{41}\) Furthermore, intrinsic (age, renal function, genetic polymorphisms) and extrinsic (drug interactions and metabolism) factors together with drug dosage (once daily vs twice daily) all lead to large interperson variability in DOACs plasma concentrations.\(^\text{26}\)\(^\text{42}\) Four small observational studies suggest recanalisation therapies (both IVT and endovascular) may be safe in patients taking DOACs within 48 hours of stroke but total numbers are small and subgroup analysis (time from last drug intake 0–4 hours, 5–12, 12–24 etc) not possible.\(^\text{11,43-45}\)

### Selection of Patients by Drug Monitoring

Table 3 summarises observational studies applying DOAC plasma levels to select patients for thrombolysis (middle paragraph, ‘DOAC plasma level based approach’: 3 studies with 36 patients). However, prior to reviewing the evidence, one needs to understand the complexities in the interpretation of drug monitoring in DOACs (see section on drug monitoring of DOACs).

A single centre study from Basel (Switzerland) reported IVT in 18 patients on rivaroxaban (3 with additional mechanical thrombectomy) using a standard operating procedure with predefined cut-offs for thrombolysis. IVT was given in patients with low (<20 ng/mL) or intermediate (20–100 ng/mL) levels of rivaroxaban and prior ingestion within 48 hours.\(^\text{28}\) There were no patients with sICH or systemic haemorrhage. A single-centre study from Erlangen (Germany) similarly used predefined plasma DOAC levels for all four available DOACs in determining whether patients were eligible (level <50 ng/mL) or potentially eligible (50–100 ng/mL) for IVT.\(^\text{46}\) In this report, 24 DOAC (apixaban 9, dabigatran 9, rivaroxaban 6) patients received IVT with 1 case (4.2%) of sICH developing in a patient who also had mechanical thrombectomy. In both studies, the median turn-around time for DOAC plasma levels (ie, time from blood sampling to first results) was 39 and 37 min, respectively.\(^\text{28}\)\(^\text{46}\) In a German multicentre study, among 150 potentially eligible patients, only 9 patients received IVT based on DOAC plasma levels without any sICH.\(^\text{8}\) Although measuring DOAC

| Study                                      | Number of patients (DOAC type) | Number of sICH/ rate | Number of patients (comparator) | Number of sICH/rate | Comment                                                                 |
|--------------------------------------------|--------------------------------|----------------------|---------------------------------|---------------------|-------------------------------------------------------------------------|
| Heterogenous or unknown selection criteria | n=5 studies, n=475 patients    | 251 (all DOAC)       | 12 (4.8%)                       | 1500 (VKA)          | 73 (4.9%) No selection criteria or information on anticoagulation available |
| Seiffge et al\(^\text{11}\)               | 78 (all DOAC)                  | 2 (3.9%)             | 441 (VKA) and 8938 (no anticoagulation) | 9.3% and 7.2%       | Heterogenous selection criteria, all within 48 hours, partly plasma level-based |
| Suzuki et al\(^\text{10}\)                | 71 (all DOAC)                  | 2%                   | n/a                             | n/a                 | National survey and case collection, (dosage of rt-PA: 0.6 mg/kg)          |
| Shajjouei et al\(^\text{14}\)            | 6 (dabigatran)                 | 0                    | n/a                             | n/a                 | Case collection                                                          |
| Meinel et al\(^\text{11}\)               | 69 (all DOAC)                  | 3.1%                 | 1544 (no anticoagulation) and 156 (VKA with INR <1.7) | 3.6% (no) and 4.6% (VKA) | 18 of 23 centres used DOAC plasma levels for patient selection |
| DOAC plasma level-based approach           | n=3 studies, n=36 patients     |                      |                                 |                     |                                                                         |
| Marsch et al\(^\text{46}\)               | 9 (all DOAC)                   | 1 (4.2%)             | 31 VKA                          | 1 (3.3%)            | All patients <48 hours of last intake                                      |
| Seiffge et al\(^\text{18}\)              | 18 (rivaroxaban)               | 0                    | n/a                             | n/a                 |                                                                         |
| Purrucker et al\(^\text{16}\)            | 9 (all DOAC)                   | 0                    | n/a                             | n/a                 |                                                                         |
| Idarucizumab (n=8 studies, n=236 patients) | 13 (dabigatran)                | 0                    | n/a                             | n/a                 | Tenecteplase                                                            |
| Barber et al\(^\text{46}\)               | 51 (dabigatran)                | 2 (3.9%)             | 1285 (all non-DOA)              | 49 (3.8%)           |                                                                         |
| Kummer et al\(^\text{46}\)               | 80 (dabigatran)                | 0                    | n/a                             |                     |                                                                         |
| Köpper et al\(^\text{46}\)               | 7 (dabigatran)                 | 0                    | n/a                             |                     |                                                                         |
| Pretnar Oblak et al\(^\text{28}\)        | 11 (dabigatran)                | 2 (18.2%)            | n/a                             | no                  | 9 with elevated thrombin time                                            |
| Giannandrea et al\(^\text{46}\)          | 55 (dabigatran)                | 3 (5.5%)             | n/a                             | n/a                 |                                                                         |
| Sanak et al\(^\text{46}\)                | 13 (dabigatran)                | 1 (7.6%)             | 2 (10%)                         | n/a                 |                                                                         |
| Fang et al\(^\text{46}\)                 | 6 (dabigatran)                 | 0                    | n/a                             |                     |                                                                         |

INR, international normalised ratio; sICH, symptomatic intracerebral haemorrhage; VKA, vitamin K antagonist.

---

**Table 3: Observational studies including patients on direct oral anticoagulant (DOAC) treated with intravenous thrombolysis**
plasma levels is theoretically time consuming, if blood is drawn directly on admission and analysis started immediately, this can be done in parallel to other tasks (obtaining NIHSS, neuroimaging). Therefore, in centres who use this approach in routine, door-to-needle times in patients selected using plasma levels are reasonable and not significantly delayed compared with patients on VKAs. Point-of-care testing using CoaguCheck to rapidly detect <30 ng/mL (for rivaroxaban) takes only less than 1 min.

**USE OF SPECIFIC REVERSAL AGENTS PRIOR TO ACUTE TREATMENT**

There are three known reversal agents to DOACs, two available (idarucizumab and andexanet alfa) and one under development (and not part of this review).

Idarucizumab is a humanised monoclonal antibody fragment with 350 times the affinity for dabigatran than dabigatran has for thrombin. Andexanet alfa is a recombinant human FXa variant which has an affinity to anti-Xa medications similar to native Xa itself, serving as a decoy. Both medications have been shown to reverse DOAC activity in a dose-dependent manner from phase 2 trials and have been used in single arm, unblinded observational studies in patients with major bleeding or major bleeding or need for urgent intervention with return to normal drug-specific activity measures (ie, anti-Xa activity) parameters within minutes. Idarucizumab has been approved by the European Medical Agency in 2015 to reverse dabigatran and andexanet alfa received conditional approval in 03/2019 for reversing rivaroxaban and apixaban (edoxaban not yet approved, preliminary data available). While andexanet alfa has not been approved for the use prior to IVT or mechanical thrombectomy as part of the current license, idarucizumab can be used according to its license for ‘patients in urgent need of intervention.’

There is a considerable number of case-reports (25 case reports including 31 patients) and one large case series (80 patients) using idarucizumab prior to IVT. Table 3 provides an overview about currently available data from observational studies (bottom paragraph, ‘Idarucizumab’: 8 studies including 236 patients) using idarucizumab, including national and hospital based data from continental Europe, New Zealand and Taiwan. Idarucizumab 5g infusion was administered without waiting for confirmation of postreversal normalisation of coagulation profile. The New Zealand national reperfusion registry compared data of patients with dabigatran reversal to non-anticoagulated patients with almost identical risk of symptomatic intracranial haemorrhage in dabigatran (3.8%) versus non-anticoagulated patients. However, idarucizumab is costly (approximately US$2400) and the cost–benefit of this approach in IVT is currently unknown; decision to treat such patients needs to be individualised.

Andexanet alfa is a novel antidote for factor Xa inhibitors and provides a rapid but non-permanent reversal of anticoagulant effect. Andexanet alfa is given as a bolus and followed by a 2 hours infusion and anti-Xa activity is reduced by ~90%. However, a rebound of Xa activity occurs following completion of infusion. Treatment is associated with 10% early thrombotic complications. There is one recent case report describing the use of andexanet alfa prior to thrombolysis in a patient with ischaemic stroke and recent intake of apixaban without bleeding or thrombotic complications. The current price for andexanet alfa is approximately US$17 570. A calibrated anti-Xa level to assess DOAC activity costs about SFr45 in Switzerland (approximately US$50).

**MECHANICAL THROMBECTOMY**

Data regarding safety and efficacy of mechanical thrombectomy in patients on DOAC rely on observational studies (table 4; 14 studies with 558 patients). A recent meta-analysis, that also includes patients on VKA, concluded that patients on VKA (sOR 1.6, 95%CI 1.2 to 2.2), but not patients on DOAC (sOR 1.0, 95%CI 0.6 to 1.8), had an increased risk of symptomatic intracranial haemorrhage after mechanical thrombectomy as compared with control patients without anticoagulation. Major limitations of the studies included different rates of IVT (prior to mechanical thrombectomy), lack of reliable assessment of activity of DOAC, inclusion of patients with subtherapeutic DOAC, missing information on DOAC reversal as well as lack of adjustment for confounding. Nevertheless, the association with increased rates of symptomatic intracranial haemorrhage remained stable after including only studies with confirmed therapeutic VKA therapy (sOR 1.7, 95%CI 1.04 to 2.6) with no significant association for patients on confirmed therapeutic DOAC therapy (sOR 1.1, 95%CI 0.4 to 2.8). Additionally, after adjustments in a large observational study, the association of VKA with symptomatic intracranial haemorrhage (sOR 2.6, 95%CI 1.3 to 4.8) remained tangible without a safety signal in patients on DOAC (sOR 0.9, 95%CI 0.3 to 3.3).

From a technical point of view, mechanical thrombectomy procedures seem feasible and successful in patients on DOAC. In a French multicentre observational study, an increased rate of successful reperfusion (modified treatment in cerebral ischemia score2b/3) in patients on DOAC as compared with patients on VKA (92.0% vs 74.3%, p 0.001) was reported. This was confirmed by another study showing that large vessel occlusion in patients on DOAC yielded excellent reperfusion rates as compared with VKA and controls (93.2% vs 81.5% vs 84.2%). The pathophysiology underlying this is unclear; however, potential differences in thrombus histology due to the different pharmacologic properties could explain these findings. The complication rates and procedure duration were comparable across the groups. All patients with large vessel occlusion qualifying for mechanical thrombectomy should be transferred to a centre where this procedure is available. Indication for IVT in patients on DOAC should not unnecessarily delay the transfer.

**EXPERT OPINION-BASED APPROACH**

Based on the available evidence, an individualised approach combining monitoring anticoagulant activity, imaging-based selection of patients most likely to benefit from acute recanalisation therapies (ie, mechanical thrombectomy for any large vessel occlusion, IVT in the presence of potentially salvageable tissue) and the use of specific reversal agents only in selected patients seems the most promising approach. Figure 2 outlines these approaches.

**FUTURE DIRECTIONS**

Future research needs to elucidate the following aspects: first, availability of DOAC monitoring needs to be improved. Streamlining central laboratory measurement and reducing turn-around times seem feasible. Point-of-care measurement for DOACs should be among the top priorities. Second, although prior reversal of anticoagulation using a specific reversal agent seems to be a reasonable and safe approach, health economics (pricing) and advanced imaging selection (salvageable tissue) given the relatively small effect size of thrombolysis on functional outcome should be considered. It seems unlikely that this approach should be generalised to all patients. Furthermore,
other available approaches—using time since last intake and DOAC monitoring—seem to provide equally safety results.

Third, DOAC patients managed with IVT beyond the standard time thrombolysis window need to be explored. Fourth, although tenecteplase is not currently licensed for treatment of ischaemic stroke, several centres have reported off-label use of tenecteplase but experience of tenecteplase with DOAC pretreatment is limited.37

CONCLUSION

This review summarises current knowledge on recanalisation therapies for acute ischaemic stroke therapy in patients taking DOACs. Available data of >450 patients receiving IVT and >550 patients receiving mechanical thrombectomy provided reassuring safety results although only from observational studies and case reports and not randomised controlled trials. The use of IVT in patients with relative contraindications (eg, prior VKA therapy, dual antiplatelet therapy or epileptic seizures at onset) has been studied with a focus on safety rather than efficacy, probably due to an overall small effect size of thrombolysis in stroke and the need for large sample sizes to find any effect. We therefore urge caution that safe treatment is not equivalent to efficacy.

Even 10 years after introduction of the first DOAC on the market, there are still a lack of large, multicentre, multinational data with thorough documentation of selection criteria and safety and efficacy outcomes. A randomised controlled trial in the setting of thrombolysis in patients taking DOACs seems very unlikely. The results of large, prospective observational studies like registry of acute stroke under novel oral anticoagulants prime will hopefully provide further new insights in this topic and additional safety data.

Despite increasing experience and data availability in IVT for DOAC patients, the literature remains relatively limited. The small number of patients likely reflects the intrinsic bias to not treat with thrombolysis in patients on DOACs, and interpretation of the data therefore needs to be considered.

In summary, although available data provide promising and reassuring safety data, several aspects including patient selection need to be addressed in future studies. Precision medicine using a tailored approach combining monitoring anticoagulant activity, imaging-based selection (visualisation of potentially salvageable tissue) with potential use of specific reversal agents seems a reasonable choice in the interim.

REVIEW CRITERIA

We (DJS, TM, JK, DW and TYW) identified references for this review by searches of PubMed on 1 May 2020, 5 May 2020 and 22 August 2020, using the search terms “(thrombolysis

### Table 4: Observational data on symptomatic intracerebral haemorrhage (sICH) risk following endovascular stroke treatment

| Study | Number of patients (DOAC type) | Number of patients (comparator) | Number of sICH/ rate | Comment (DOAC group) |
|-------|--------------------------------|---------------------------------|----------------------|----------------------|
| Seiffge et al | 27 (all DOAC) | 27 (VKA and 43 no anticoagulation) | 6 (22%) and 2 (5%) | Heterogenous selection criteria, all within 48 hours, partly plasma level based. |
| Rebello et al | 17 (all DOAC) | 29 (VKA and 265 no anticoagulation) | 5 (17%) and 27 (10%) | All within 24 hours; PH1, PH2 and SAH defined as sICH. |
| Rebello et al | 73 (all DOAC) | 142 (VKA and 1052 no anticoagulation) | 13 (9%) and 57 (5%) | No selection criteria or information on anticoagulation available. |
| Purucker et al | 28 (all DOAC) | NA | Drug-specific coagulation tests indicated through drug concentrations in the majority of patients, no comparator. |
| Zapata-Wainberg et al | 9 (all DOAC) | 104 (VKA and 389 no anticoagulation) | 4 (4%) and 28 (7%) | No selection criteria or information on anticoagulation available. |
| Kurowski et al | 16 (all DOAC) | 51 (VKA and 453 no anticoagulation) | 7 (14%) and 32 (7%) | No selection criteria or information on anticoagulation available. |
| Suzuki et al | 44 (all DOAC) | 7 (VKA and 23 no anticoagulation) | 0 (0%) and 0 (0%) | No selection criteria or information on anticoagulation available, recall bias. |
| Cernik et al | 15 (not specified) | 50 (VKA and 615 no anticoagulation) | 6 (12%) and 31 (5%) | No selection criteria or information on anticoagulation available. |
| Hoyer et al | 10 (not specified) | 30 (no anticoagulation) | 1 (3%) | No selection criteria or information on anticoagulation available. |
| Wong et al | 13 (all DOAC) | 23 (VKA and 66 no anticoagulation) | 1 (4%) and 1 (2%) | No selection criteria or information on anticoagulation available. |
| Krajickova et al | 5 (all DOAC) | 21 (VKA and 259 no anticoagulation) | 2 (10%) and 21 (8%) | No selection criteria or information on anticoagulation available. |
| Meinel et al | 98 (all DOAC) | 69 (VKA and 1612 no anticoagulation) | 5 (7%) and 84 (5%) | See below for patients with confirmed therapeutic DOAC therapy only. |
| L’Allinec et al | 105 (all DOAC) | 97 (VKA) | 12 (12%) | Last intake within 24 hours, specific drug levels not available. |
| Goldhoorn et al | 98 (not specified) | 404 (VKA and 2660 no anticoagulation) | 23 (6%) and 162 (6%) | No selection criteria or information on anticoagulation available. |
| DOAC plasma-level based approach (n=2 studies, n=56 (patients)) | | | | |
| Seiffge et al | 7 (rivaroxaban) | NA | 3 of 7 low or intermediate drug level |
| Meinel et al | 49 (all DOAC) | 222 (VKA and 1612 no anticoagulation) | 21 (9.5%) and 84 (5%) | Ascertained compliance or therapeutic drug levels |

DOAC, direct oral anticoagulant; PH, parenchymal haemorrhage; VKA, vitamin K antagonist.
Cerebrovascular disease

Patient with acute ischaemic stroke on DOAC

- Thrombus amenable to MT
  - MT recommended
  - no

- DOAC time from ingestion ≥ 48 hours (and CrCl >50 ml/min)
  - IVT recommended
  - no

Dabigatran

- Normal TT or
  - Dilute TT < 4xULN, ECT < 2xULN, Dabigatran level <30 ng/ml
  - yes

  - Consider* Idarucizumab + IVT
  - no

  - IVT recommended

Rivaroxaban/Apixaban/Edoxaban

- No drug-specific coagulation assay available
  - Drug-specific anti-Xa level <30 ng/ml
  - yes

- Drug-specific anti-Xa level 30-100 ng/ml
  - no

  - IVT recommended

Anexanet alfa + IVT: no systematic data available consider short duration/rebound and potentially increased pro-thrombotic risk

*Consider IVT if:
- Severe disability
- Large penumbra

Figure 2 Expert-opinion-based approach for patient selection within the 4.5 hours time window. Decision for intravenous thrombolysis (IVT) should not delay thrombectomy (eg, direct thrombectomy or immediate transfer to a thrombectomy-capable centre recommended). AHA/ASA, American Heart/Stroke Association; APTT, activated partial thrombin time; DOAC, direct oral anticoagulant; ECT, ecarin clotting time; INR, international normalised ratio; MT, mechanical thrombectomy; PT, prothrombine time; TT, thrombin time; ULN, upper limit normal.

OR IVT OR rtPA OR tPA OR mechanical thrombectomy OR endovascular therapy OR MT OR EVT) AND (DOAC OR rivaroxaban OR dabigatran OR edoxaban OR apixaban OR DOAC OR direct oral anticoagulants OR novel oral anticoagulants OR Non-Vitamin K oral anticoagulants) AND (ischaemic stroke OR ischemic stroke)”. One author (DJS) additionally searched EMBASE and Web of science on 12 December 2020. We have excluded Betrixaban from our review due to limited availability outside the US and limited indication label. Additionally, we searched our personal records and abstracts from international conferences in the past 10 years (2010–2020) for relevant publications or data. We selected publications presenting original data and published in English if they reported ≥5 patients on DOACs who received recanalisation therapies. In addition, we searched PubMed, personal records and an internet search engine (ie, Google Scholar) using the search terms “guidelines”, “thrombolysis”, “stroke” and “oral anticoagulation” OR “DOAC” OR “direct oral anticoagulants” to identify guidelines from relevant organisations (national or international expert committees).

Contributors DJS, DW and TYW: concept of the study. DJS, TM, JK, DW and TYW: first draft of the manuscript. All authors: critical revision of the manuscript for important intellectual content.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests DJS: advisory board: Bayer and Pfizer (manufacturer of Rivaroxaban and Apixaban); personal fees used for research funding: Portola (manufacturer of Andexanet alfa). Research funding from the Swiss National Science Foundation, the Bangerter–Rhyner Foundation, the Swiss Society of Neurology and the Bayer Foundation unrelated to the submitted work. JK: Grants from SAMW/ Bangerter, CTU Bern, Swiss Stroke Society. UF: reports other from CSL Behring, Medtronic and Stryker unrelated to the submitted work.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
David J Seiffge http://orcid.org/0000-0003-3890-3849
Jan Christoph Purrucker http://orcid.org/0000-0003-2978-4972
Johannes Kaesmacher http://orcid.org/0000-0002-9177-2289
Teddy Y Wu http://orcid.org/0000-0003-1845-1769

REFERENCES
1. Seiffge DJ, De Marchis GM, Koga M, et al. Ischemic stroke despite oral anticoagulant therapy in patients with atrial fibrillation. Ann Neurol 2020;87:677–87.
2. Ebner M, Birschmann I, Peter A, et al. Point-Of-Care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants. Crit Care 2017;21:32.
3. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American heart Association/American stroke association. Stroke 2018;49:e46–110.
4. Turc G, Bhogal P, Fischer U, et al. European Stroke Organisation (ESO) - European Society for Minimally Invasive Neurological Therapy (ESMINT) Guidelines on Mechanical Thrombectomy in Acute Ischaemic StrokeEndorsed by Stroke Alliance for Europe (SAFE). Eur Stroke J 2019;4:6–12.
5. Emberson J, Lees KR, Lyden P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014;384:1929–35.
6. Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet 2016;387:1723–31.
7. Yang P, Zhang Y, Zhang L, et al. Endovascular thrombectomy with or without intraoperative alteplase in acute stroke. N Engl J Med 2020;382:1981–93.
8 Purrucker JC, Haas K, Rizos T et al. Coagulation testing in acute ischemic stroke patients taking non-vitamin K antagonist oral anticoagulants. Stroke 2017;48:152–8.
9 Rizos T, Herweh C, Jenetey E et al. Point-Of-Care international normalized ratio testing accelerates thrombolysis in patients with acute ischemic stroke using oral anticoagulants. Stroke 2009;40:3547–51.
10 Suzuki K, Aoki J, Inokoshi S et al. Low risk of ICH after reperfusion therapy in acute stroke patients treated with direct oral anti-coagulant. J Neurol Sci 2017;379:207–11.
11 Seiffge DJ, Hooff R-J, Nothe CH et al. Recalcification therapies in acute ischemic stroke patients: impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome. Circulation 2015;132:1261–9.
12 Xian Y, Friederspiel JJ, Hernandez AF et al. Use of intravenous recombinant tissue plasminogen activator in patients with acute non-vitamin K antagonist oral anticoagulants preceding tPA. Stroke 2014;45:2237–9.
13 Touzi E, Gruel Y, Gouin-Thibault J et al. Intravenous thrombolysis for acute ischemic stroke in patients on direct oral anticoagulants. Eur J Neuro 2018;25:747–52.
14 Seiffge DJ, Kägi G, Michel P et al. Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage. Ann Neurol 2018;83:451–9.
15 Gong II, Kim RB. Importance of pharmacokinetic profile and variability as determinants of thrombolysis and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol 2013;29:524–32.
16 Wong JW, Churilov L, Dowling R et al. Safety of endovascular thrombectomy for acute ischaemic stroke in anticoagulated patients ineligible for intravenous thrombolysis. Cerebrovasc Dis 2018;46:193–9.
17 Purrucker JC, Wolf M, Haas K et al. Safety of endovascular thrombectomy in patients receiving non-vitamin K antagonist oral anticoagulants. Stroke 2016;47:1127–30.
18 Seiffge DJ, Haas K, Meinel A et al. Intravenous thrombolysis for acute ischemic stroke in the setting of anticoagulation. Stroke 2015;46:5366–9.
19 Marasch A, Macha K, Siedler G et al. Direct oral anticoagulant plasma levels for the management of acute ischemic stroke. Cerebrovasc Dis 2019;48:17–25.
20 Seiffge DJ, Traenka C, Polymeris A et al. Feasibility of rapid measurement of rivaroxaban plasma levels in patients with acute stroke. J Thromb Thrombolysis 2020;50:386–91.
21 Meinel TR, Kniepert JU, Seiffge DJ et al. Endovascular stroke treatment and risk of intracranial hemorrhage in anticoagulated patients. Stroke 2020;51:892–8.
22 Connolly SJ, Crowther M, Eikelboom JW et al. Full study report of Andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 2019;380:1326–35.
23 Pollack CV, Reilly PA, Eikelboom J et al. Idarucizumab for dabigatran reversal. N Engl J Med 2019;381:379–91.
24 Lu G, Conley PB, Leeds DM et al. A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers. Blood Adv 2020;4:728–39.
25 Kermer P, Eschenfelder CC, Diener HC et al. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany—Updated series of 120 cases. Int J Stroke 2020;15:609–18.
26 Pretnar Ovlak, J Sabovic M, P So. Intravenous thrombolysis after Idarucizumab application in acute stroke Patients-A potentially increased sensitivity of thrombo lysis? J Stroke Cerebrovasc Dis 2019;28:768–73.
27 Kupper C, Fell K, Klein M, et al. Idarucizumab administration in emergency situations: the Munich registry of Pradaxa® in clinical routine (Mr Pradaxa). Neu ral 2019;26:8071–11.
28 Šafář D, Jakubček S, Čermák D et al. Intravenous thrombolysis in patients with acute ischemic stroke after a reversal of dabigatran anticoagulation with Idarucizumab: a real-world clinical experience. J Stroke Cerebrovasc Dis 2018;27:2479–83.
29 Fang C-W, Tsai Y-T, Chou P-C et al. Intravenous thrombolysis in acute ischemic stroke after Idarucizumab reversal of dabigatran effect: analysis of cases from the Taiwan Stroke Cerebrovasc Dis 2019;28:615–20.
30 Kallmünzer B, Brett M, Schlueter F et al. Endovascular application by Kallmünzer et al regarding Article, “Safety of Intravenous Thrombolysis Among Patients Taking Direct Oral Anticoagulants: A Systematic Review and Meta-Analysis” - Stroke 2020;51:130–1.
31 L’Allinec V, Sibon I, Mazighi M et al. MT in anticoagulated patients: direct oral anticoagulants versus vitamin K antagonists. Neurology 2020;94:e842–50.
32 Mazya MV, Lees KR, Markus R et al. Safety of intravenous thrombolysis for ischemic stroke in patients treated with warfarin. Ann Neurol 2013;74:266–74.
33 Xian Y, Liang L, Smith EE et al. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. JAMA 2012;307:2600–8.
34 Tsivgoulis G, Katzanis AH, Mavridis D et al. Intravenous thrombolysis for ischemic stroke patients on dual antiplatlets. Ann Neurol 2018;84:89–97.
35 Tsivgoulis G, Katzanis AH, Zand R et al. Plateletae pretreatment and outcomes in intravenous thrombolysis for stroke: a systematic review and meta-analysis. J Neurol 2017;264:1227–35.
36 Polymenis AA, Curtez S, Eurdy H et al. Intravenous thrombolysis for suspected ischemic stroke with seizure at onset. Ann Neurol 2019;86:770–9.
37 Haas K, Purrucker JC, Rizos T et al. Rationale and design of the registry of acute stroke under novel oral Anticoagulants-prime (RASUNOA-prime). Stroke J 2019;194:181–8.
38 Powers WJ, Rabinstein AA, Ackerson T et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the management of acute ischemic stroke. Cerebrovasc Dis 2019;48:17–25.